The IGFBP1 DNA methylation levels at each of the six CpG sites were significantly higher in both newly diagnosed type 2 diabetes patients (P1 24.3%, P2 17.5%, P3 15.0%, P4 16.4%, P5 21.3% and P6 24.7%) and treated patients (P1 24.6%, P2 18.2%, P3 15.8%, P4 16.2%, P5 21.6% and P6 24.7%) compared with those in non-diabetic subjects (P1 17.7%, P2 15.6%, P3 12.7%, P4 13.%, P5 19.5% and P6 22.%) (P < 0.001 for all comparisons vs. non-diabetic controls) (Figure 1A). Here, IGFBP1 is linked to type 2 diabetes mellitus.